Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 571

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 571
---
 are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheets. The following is a reconciliation of the Company’s common stock subject to possible redemption as of September 30, 2024:

|                                                                         |     | Common Stock 
 Subject to   
 Possible     
 Redemption   |             |   |
|:------------------------------------------------------------------------|:----|:-------------|------------:|:--|
| Gross proceeds from Initial Public Offering                             |     | $            |  69,000,000 |   |
| Less: Proceeds allocated to public warrants and rights                  |     |              |  (1,236,527 | ) |
| Offering costs allocated to common stock subject to possible redemption |     |              |  (4,791,126 | ) |
| Less: Redemption of common stock in connection with Trust extension     |     |              | (35,995,728 | ) |
| Plus: Accretion on common stock subject to possible redemption          |     |              |   9,449,634 |   |
| Balance, December 31, 2023                                              |     | $            |  36,426,253 |   |
| Less: Redemption of common stock in connection with Trust extension     |     |              | (17,045,763 | ) |
| Plus: Accretion on common stock subject to possible redemption          |     |              |   1,288,019 |   |
| Balance, September 30, 2024                                             |     | $            |  20,668,509 |   |

NOTE 7 — STOCKHOLDERS’ DEFICIT Preferred Stock The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. As of September 30, 2024 and December 31, 2023, there were no shares of preferred stock issued or outstanding. Common Stock Pursuant to the Charter, the Company is authorized to issue 100,000,000 shares of Common Stock, $0.0001 par value.

F-21 BELLEVUE LIFE SCIENCES ACQUISITION CORP. NOTES TO CONDENSED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 (UNAUDITED) NOTE 7 — STOCKHOLDERS’ DEF